Loyalties in clinical research on drugs: The case of hormone replacement therapy

Social Science and Medicine

Volumn 63, Issue 2, 2006, Pages 540-551

  Palmlund, Ingar ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

Bourdieu; Clinical trials; Hormone replacement therapy; HRT; Menopause

Indexed keywords

ESTROGEN;

CANCER; CARDIOVASCULAR DISEASE; DRUG; ESTROGENIC COMPOUND; HORMONE; HOSPITAL SECTOR; WOMENS HEALTH;

ARTICLE; CANCER; CLINICAL TRIAL; HEART DISEASE; HORMONE SUBSTITUTION; HUMAN; MEDICAL ETHICS; MEDICAL RESEARCH;

CLINICAL TRIALS; DRUG INDUSTRY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIAN-PATIENT RELATIONS; TRUST;

EID: 33646842827     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2005.06.057     Document Type: Article

References (67)

1. Aburdene P., and Naisbitt J. Megatrends for women (1992), Villard Books, New York
2. Alving, B. (2004). NIH asks participants in Women's Health Initiative Estrogen Alone Study to stop study pills, begin follow-up phase. NIH News, March 2.
3. American Medical Association, Council on Pharmacy and Chemistry. (1939). Stilbestrol: Preliminary Report to the Council. Journal of the American Medical Association, 113, 2312.
4. Angell M. The truth about the drug companies: How they deceive us and what to do about it (2004), Random House, New York
5. Antunes C.M., Strolley P.D., Rosenshein N.B., Davies J.L., Tonascia J.A., Brown C., et al. Endometrial cancer and estrogen use. New England Journal of Medicine 300 1 (1979) 9-13
6. Aristotle. Nicomachean ethics (1987), Penguin, Harmondsworth, UK
7. Auchincloss H., and Haagensen C.D. Cancer of the breast possibly induced by estrogenic substance. Journal of the American Medical Association 111 16 (1940) 1517-1523
8. Beauchamp T.L., and Childress J.F. Principles of biomedical ethics (1979), Oxford University Press, Oxford
9. Beral V., and Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 9382 (2003) 419-497 and subsequent correspondence
10. Bergkvist L., Adami HO., Persson I., Hoover R., and Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. New England Journal of Medicine 321 5 (1989) 293-297
11. Bourdieu P. Distinction: Critique sociale du jugement (1979), Editions de Minuit, Paris
12. Bourdieu P. Homo Academicus (1984), Editions de Minuit, Paris
13. Bourdieu P. Raisons pratiques: Sur la théorie de l'action (1994), Editions du Seuil, Paris
14. Bren, L. (2003).The estrogen and progestin dilemma: New advice, labeling guidelines. FDA Consumer Magazine, March-April.
15. Claybrook J., and staff at Public Citizen. Retreat from safety (1987), Pantheon Books, New York
16. Dejanikus, T. (1985). Major drug manufacturer funds osteoporosis public education campaign. National Women's Health Network News, (May/June), 1,3,8.
17. Doisy E.A. The estrogenic substances. Glandular physiology and therapy (1942), American Medical Association, Chicago
18. Elliott, S. (2004). Advertising: Proposed changes to ad rules. The New York Times, February 5.
19. Ettinger B. Hormone replacement therapy and coronary heart disease. Obstetrics and Gynecology Clinics of North America 17 4 (1990) 741-757
20. European Agency for the Evaluation of Medicinal Products (2003). EMEA public statement on recent publications regarding hormone replacement therapy. EMEA/33065/03.
21. Federal Register. (1982). 47(20), 7299; 47(21), 7458.
22. Federal Register. (1985). 50(36), 7452-7591.
23. Federal Register. (1986). 51(70), 125684.
24. Federal Register. (2004). 69(31), 7492-7493.
25. Fenton A. The demise of HRT? The long-term safety of hormone replacement therapy. Expert Opinion on Drug Safety 2 4 (2003) 341-345
26. Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., et al., HERS Research Group (2002). Cardiovascular disease outcome during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). Journal of the American Medical Association, 288 (1), 49-57 (9) 1064.
27. In: Grady D., and Cummings S.R. (Eds). Postmenopausal hormone therapy for prevention of fractures. Editorial. Journal of the American Medical Association 285 22 (2001) 2909-2910
28. Hawkinson L.F. The menopausal syndrome. One thousand consecutive patients treated with estrogen. Journal of the American Medical Association 111 5 (1938) 390-393
29. Hemminki E., and McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: Pooled data from clinical trials. British Medical Journal 315 7101 (1997) 149-153
30. Hersh A.L., Stefanick M.L., and Stafford R.S. National use of postmenopausal hormone therapy: Annual trends and response to recent events. Journal of the American Medical Association 291 1 (2004) 104-106
31. Hoover R., Gray L., Cole P., and Macmahon B. Menopausal estrogens and breast cancer. New England Journal of Medicine 295 8 (1976) 401-405
32. Horwitz R.I., and Feinstein A.R. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. New England Journal of Medicine 229 20 (1978) 1089-1094
33. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association 280 7 (1998) 605-613
34. International Agency for Research on Cancer. (1999). Hormonal contraception and post-menopausal hormonal therapy. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans (Vol. 72).
35. International Menopause Society. Response of the International Menopause Society to EMEA Recommendation. Climacteric 7 (2004) 2
36. International Menopause Society, ExecutiveCommittee. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Climacteric 7 (2004) 8-11
37. Kimbrough R.A., and Israel L.S. The use and abuse of estrogen. Journal of the American Medical Association 138 17 (1948) 1220
38. Krimsky S. Science in the private interest: Has the lure of profits corrupted biomedical research? (2003), Rowman and Littlefield, Oxford, UK
39. Lacassagne A. Apparition d'adénocarcinomes mammaires chez des souris mâles traités par une substance oestrogène synthetique. Comptes Rendus des Séances de la Société de Biologie 129 (1938) 641-643
40. Majumdar S.R., Almasi E.A., and Stafford R.S. Promotion and prescribing of hormone therapy after report of harm by the Women's Health Initiative. Journal of the American Medical Association 292 16 (2004) 1983-1988
41. Marks, H. M. (1997). The progress of experiment: Science and therapeutic reform in the United Sates, 1900-1990 (pp. 155-163). Cambridge University Press: Cambridge, UK.
42. In: McFarland J.E. (Ed). The menopause. Letter to the editor. Journal of the American Medical Association 156 123 (1954) 1237
43. Merton R.K. The sociology of science (1973), Chicago University Press, Chicago
44. Morris, L. A., Mazis, B., & Barofsky, I. (Eds.), (1980). Product labeling and health risks. Banbury Report 6. New York: Cold Spring Harbor Laboratory.
45. Palmlund I. Risk evaluation and estrogens. International Journal of Risk & Safety in Medicine 2 (1991) 321-342
46. Palmlund I. The social construction of menopause as risk. Journal of Psychosomatic Obstetrics and Gynecology 18 2 (1997) 87-94
47. Palmlund I. The marketing of estrogens for menopausal and postmenopausal women. Journal of Psychosomatic Obstetrics and Gynecology 18 2 (1997) 158-164
48. Pearson, C. (2002). Response to the announcement that health risks outweigh benefits for combined estrogen plus progestin. http://nwhn.org/action/archives_details.php?aaid=8. Accessed December 1, 2004.
49. Peterson M. (2002). Wyeth stock falls 24% after report. The New York Times, July 10, A16.
50. Pharmaceutical Manufacturers' Association et al. v. Food and Drug Administration et al. (1977). Civil No. 77-291, US District Court, Delaware, October 5, 1977.
51. Rapp, S.R., Espeland, M.A., Shumaker, S.A., Henderson, V.W., Brunner, R.L., Manson, J.E. et al., WHIMS Investigators (2003). Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. Journal of the American Medical Association, 289 (20), 2663-2672.
52. Roussow J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al., Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 288 3 (2002) 321-333
53. Seaman B., and Seaman G. Women and the crisis in sex hormones (1977), The Book Press, Brattleboro, VT
54. Seaman B. The greatest experiment ever performed on women: Exploding the estrogen myth (2003), Hyperion, New York
55. Sheehy G. Menopause: The silent passage (1991), Random House, New York
56. Shumaker, S.A., Legault, C., Rapp, S.R., Thal, L., Wallace, R.B., Ockene, J.K. et al., WHIMS Investigators (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. Journal of the American Medical Association, 289 (20), 2651-2662.
57. Smith D.C., Prentice R., Thompson D.J., and Herrman W.L. Association of exogenous estrogen and endometrial carcinoma. New England Journal of Medicine 293 23 (1975) 1164-1167
58. Spake, A. (2002). The menopause marketplace. US News & World Report, November 11, 42, 44-46, 48-50.
59. Stampfer M.J., and Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Medicine 20 1 (1991) 47-63
60. The Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. Controlled Clinical Trials 19 (1998) 61-109
61. Torgerson D.J., and Bell-Syer S.E.M. Hormone replacement therapy and prevention of nonvertebral fractures: A meta-analysis of randomized trials. Journal of the American Medical Association 285 22 (2001) 2891-2897
62. US District Court for the Eastern District of Arkansas Western Division. (2004). Prempro Products Liability Litigation. MDL Docket No. 4:03CV1507 WRW.
63. White C. Second long term HRT trial stopped early. British Medical Journal 325 7371 (2002) 987
64. Wilson R.A. Feminine forever (1966), M. Evans, New York
65. World Health Organization. Scientific Group. (1981). Research on menopause. Technical Report Series 670.
66. World Medical Association, General Assembly. (1948). The Declaration of Geneva, 1948, amended by the 22nd World Medical Assembly in 1968.
67. Ziel H.K., and Finkle W.D. Increased risks of endometrial carcinoma among users of conjugated estrogens. New England Journal of Medicine 293 23 (1975) 1167-1170